Result of AGM

BioVentix PLC

06 December 2024

 

Bioventix plc

("Bioventix" or the "Company")

Result of AGM

Bioventix plc (AIM: BVXP) a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that at its Annual General Meeting held yesterday, all resolutions put to shareholders were duly passed.

For further information please contact:

Bioventix plc		Tel: [phone]
Peter Harrison	Chief Executive Officer
Bruce Hiscock	Chief Financial Officer
Cavendish Capital Markets Limited		Tel: [phone]
Geoff Nash / Elysia Bough	Corporate Finance
Nigel Birks / Harriet Ward	ECM

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

 

END